Clinical Characteristics of Vivax Malaria and Analysis of Recurred Patients
2
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Background: Plasmodium vivax malaria is an acute debilitating illness characterized by recurrent paroxysmal fever and relapses from hypnozoites in the liver. Although a few studies reported clinical characteristics of vivax malaria in civilians after reemergence in the Republic of Korea, only a small group of patients was analyzed. Materials and Methods: We retrospectively reviewed the medical records of patients who had been diagnosed with vivax malaria by peripheral blood smear in a university-affiliated hospital located in a malaria-endemic area between January 2005 and December 2009. Results: During the study period, a total of 352 malarial cases from 341 patients were diagnosed. Vivax malaria was most commonly developed in July and August, 24.7% (87/352), and 21.9% (77/352), respectively. The mean (SD) age was 42.5(14.7) years and the number of male patients was 243 (71.3%). Six patients had a previous history of vivax malaria from 6months to 10 years before. A total of 337 patients (98.8%) had fever and the mean (SD) body temperature was 38.3 (1.4)°C. Common associated symptoms were chills (213/341, 62.5%), headache (115/341, 33.7%), and myalgia (85/341, 24.9%). Laboratory findings included thrombocytopenia (340/341, 99.7%), anemia (97/341, 28.5%), leukopenia (148/341, 43.4%),increase of aspartate transaminase (177/341, 51.9%), and increase of alanine transaminase (187/341, 54.8%). Hypotension (14/341, 4.1%), altered mentality (3/341, 0.9%), azotemia (3/341, 0.9%), spleen infarction (2/341, 0.6%), and spleen rupture (1/341, 0.3%) developed as complications. Chloroquine was administered to all patients and primaquine was administered with mean (SD) 3.39 (0.82) mg/kg to 320 patients. There were 11 recurrent infections during the study period. The median (range) time to recurrent infection was 100 (32–285) days. Platelet counts were higher (86,550 vs. 56,910/mm3) and time to treatment of malaria was shorter (5 vs. 7 days) in relapsed cases compared with first occurrence cases (P =0.046). Conclusions: The overall recurrence rate of vivax malaria was 3.2% (11/341) in this study. In recurred cases, malaria was diagnosed earlier and thrombocytopenia was less severe. To evaluate the risk factors associated with recurrence and adequate dose of primaquine in Korean patients, further large-scale prospective studies will be needed.
Abstract
Background: Plasmodium vivax malaria is an acute debilitating illness characterized by recurrent paroxysmal fever and relapses from hypnozoites in the liver. Although a few studies reported clinical characteristics of vivax malaria in civilians after reemergence in the Republic of Korea, only a small group of patients was analyzed. Materials and Methods: We retrospectively reviewed the medical records of patients who had been diagnosed with vivax malaria by peripheral blood smear in a university-affiliated hospital located in a malaria-endemic area between January 2005 and December 2009. Results: During the study period, a total of 352 malarial cases from 341 patients were diagnosed. Vivax malaria was most commonly developed in July and August, 24.7% (87/352), and 21.9% (77/352), respectively. The mean (SD) age was 42.5(14.7) years and the number of male patients was 243 (71.3%). Six patients had a previous history of vivax malaria from 6months to 10 years before. A total of 337 patients (98.8%) had fever and the mean (SD) body temperature was 38.3 (1.4)°C. Common associated symptoms were chills (213/341, 62.5%), headache (115/341, 33.7%), and myalgia (85/341, 24.9%). Laboratory findings included thrombocytopenia (340/341, 99.7%), anemia (97/341, 28.5%), leukopenia (148/341, 43.4%),increase of aspartate transaminase (177/341, 51.9%), and increase of alanine transaminase (187/341, 54.8%). Hypotension (14/341, 4.1%), altered mentality (3/341, 0.9%), azotemia (3/341, 0.9%), spleen infarction (2/341, 0.6%), and spleen rupture (1/341, 0.3%) developed as complications. Chloroquine was administered to all patients and primaquine was administered with mean (SD) 3.39 (0.82) mg/kg to 320 patients. There were 11 recurrent infections during the study period. The median (range) time to recurrent infection was 100 (32–285) days. Platelet counts were higher (86,550 vs. 56,910/mm3) and time to treatment of malaria was shorter (5 vs. 7 days) in relapsed cases compared with first occurrence cases (P =0.046). Conclusions: The overall recurrence rate of vivax malaria was 3.2% (11/341) in this study. In recurred cases, malaria was diagnosed earlier and thrombocytopenia was less severe. To evaluate the risk factors associated with recurrence and adequate dose of primaquine in Korean patients, further large-scale prospective studies will be needed.
참고문헌 (19)
- 염준섭, "삼일열 말라리아의 진단과 치료", 대한내과학회지, 77(1), pp.52~54 (2009), 대한내과학회
- "Diseasesweb statistics system"[URL]
- Krudsood S, "High-dose primaquineregimens against relapse of Plasmodium vivaxmalaria", Am J Trop Med Hyg, 78, pp.736~740 (2008)
- Baird JK, "Primaquine therapy for malaria", ClinInfect Dis, 39, pp.1336~1345 (2004)
- Goller JL, "Regional differencesin the response of Plasmodium vivax malaria toprimaquine as anti-relapse therapy", Am J Trop Med Hyg, 76, pp.203~207 (2007)
- Pukrittayakamee S, "A comparison of two short-courseprimaquine regimens for the treatment and radical cure ofPlasmodium vivax malaria in Thailand", Am J Trop Med Hyg, 82, pp.542~547 (2010)
- 구경본, "경기 고양지역 일개병원에서 4년간 관찰된 토착형 말라리아 79예의 임상상의 변화", Korean Journal of Family Medicine, 25(5), pp.403~410 (2004), 대한가정의학회
- Song HH, "Clinical features of Plasmodium vivax malaria", KoreanJ Med, 63, pp.546~551 (2002)
- 고동훈, "군내 삼일열 말라리아 반복 입원 환자 분석", 대한내과학회지, 68(6), pp.611~618 (2005), 대한내과학회
- 염준섭, "재출현 이후 국내 삼일열 말라리아 발생 현황", Infection and Chemotherapy, 40(4), pp.191~198 (2008), 대한감염학회
- Park JW, "Status of Plasmodium vivax malaria in the Republic of Korea after reemergence", Hanyang Med Rev, 30, pp.176~186 (2010)
- Kho WG, "Reemergence of malaria in Korea", J Korean MedAssoc, 50, pp.959~966 (2007)
- "Treatment ofMalaria: Guidelines For Clinicians (United States"[URL]
- Yi KJ, "A relapsed caseof imported tertian malaria after a standard course of hydroxychloroquineand primaquine therapy", Korean J Parasitol, 36, pp.143~146 (1998)
- Baird JK, "Chloroquine resistance in Plasmodium vivax", AntimicrobAgents Chemother, 48, pp.4075~4083 (2004)
- Lee KS, "Short report: chloroquine-resistant Plasmodium vivax inthe Republic of Korea", Am J Trop Med Hyg, 80, pp.215~217 (2009)
- Schwartz E, "Short report: aconsideration of primaquine dose adjustment for radicalcure of Plasmodium vivax malaria", Am J Trop Med Hyg, 62, pp.393~395 (2000), Am J Trop Med Hyg
- Takeuchi R, "Directly-observed therapy (DOT) for the radical 14-dayprimaquine treatment of Plasmodium vivax malaria on theThai-Myanmar border", Malar J, 9, pp.308~ (2010)
- Duarte EC, "Association ofsubtherapeutic dosages of a standard drug regimen withfailures in preventing relapses of vivax malaria", Am J TropMed Hyg, 65, pp.471~476 (2001)